For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Summary
Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.
This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions.
The report includes as follows:
The report provides current data, historical overview and future forecast.
The report includes an in-depth analysis of the Global market for Postmenopausal Vaginal Atrophy Treatment , covering Global total and major region markets.
The data of 2017-2025 are included. All-inclusive market are given through data on sales, consumption, and prices (Global total and
By major regions).
The report provides introduction of leading Global manufacturers.
Postmenopausal Vaginal Atrophy Treatment market prospects to 2025 are included (in sales, consumption and price).
Market Segment as follows:
By Region / Countries
- North America (U.S., Canada, Mexico)
- Europe (Germany, U.K., France, Italy, Russia, Spain etc)
- Asia-Pacific (China, India, Japan, Southeast Asia etc)
- South America (Brazil, Argentina etc)
- Middle East & Africa (Saudi Arabia, South Africa etc)
By Type
- Creams
- Tablets
- Patches
- Rings
By End-User / Application
- Topical Estrogen
- Systemic Estrogen
- Non-hormonal Therapy
By Company
- Allergan
- Pfizer
- Shionogi
- Novo Nordisk
- Teva Pharmaceutical
- Bayer.